Gilead Sciences, Inc. $GILD Shares Sold by Beech Hill Advisors Inc.

Key Points

• Beech Hill Advisors Inc. has reduced its stake in Gilead Sciences by 22.2%, owning 11,033 shares valued at approximately $1.22 million after selling 3,155 shares.
• Gilead's CEO and CFO recently sold shares valued at over $1.4 million, with insiders collectively selling 71,500 shares worth $8.28 million in the last ninety days.
• Gilead Sciences has received multiple analyst upgrades, raising price targets and ratings, highlighting a consensus average target price of $121.14 for investors.

Beech Hill Advisors Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 22.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,033 shares of the biopharmaceutical company's stock after selling 3,155 shares during the quarter. Beech Hill Advisors Inc.'s holdings in Gilead Sciences were worth $1,223,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after acquiring an additional 1,520,809 shares during the period. Nuveen LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter valued at about $620,415,000. Finally, Nordea Investment Management AB increased its stake in shares of Gilead Sciences by 39.8% in the 2nd quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company's stock valued at $436,648,000 after purchasing an additional 1,126,886 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company's stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,500 shares of company stock worth $8,281,540 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Rothschild & Co Redburn boosted their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a report on Friday, September 12th. Citigroup boosted their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Wednesday, October 8th. BMO Capital Markets raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "outperform" rating in a research report on Monday. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. Finally, Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the company from $108.00 to $127.00 in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $121.14.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $123.11 on Tuesday. The stock has a market cap of $152.76 billion, a PE ratio of 24.52, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34. The stock has a 50-day moving average of $115.27 and a 200-day moving average of $110.62. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a one year low of $85.60 and a one year high of $124.11.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.